Aarkstore Enterprise---china Diabetes Market Report & Outlook For 2010-2015

As the second largest economy of the world, China enjoys pink of health but its affluence

is giving rise to another sickness- a rapid increase in a life-style disease called diabetes. With the Chinese Population getting richer, fatter and less mobile, there has been a surge in the prevalence of diabetes. Further fuelled by rising disposable incomes, the diabetes market- Non-Insulin Anti-diabetics and Insulin, is expanding by more than 25% percent a year, and thus creating lucrative opportunities for global pharmaceutical companies at a time when rates in the more developed markets have declined.

Chinas diabetes market grew at CAGR of 26% in the last five years with sales touching US$ 642 Million in 2009. In a country with around 10% of the total population being above 65 years of age, nearly 100 Million people obese and overweight, and with urbanization rates in an increasing mode, we expect the market to more than quadruple vis--vis its present level by 2015.

IMARCs new report China Diabetes Market Outlook (2010-2015) gives a deep insight into the Chinese diabetes market. The research study serves as an analytical as well as statistical tool to understand the epidemiology, trends, market structure and segmentation, competitive landscape, drivers, restraints and the outlook of the diabetes market in China. The report can serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are looking to foray into the Chinese diabetes market in some form or the other.

Report Highlights

*

Driven by strong performance of both Insulin and Non-Insulin Anti-diabetics, The Chinese diabetes market is expected to exceed US$ 2.8 Billion by 2015.

*

In 2009, the market for Non-Insulin Anti-diabetics was worth US$ 357 Million. Four of the top five players were foreign multinationals, with Bayer being the leader with a 28% market share.

*

Alpha Glycosidase Inhibitors represented the biggest non Insulin Anti-diabetes class with a share of 35% in 2009.

*

Although DPP-IV Inhibitors have been available in China only since march 2010. We expect this class to show a strong uptake in the next five years and reach revenues worth US$ 172 Million.

*

Chinas Insulin market witnessed a CAGR growth of 31% between 2005-2009 and was worth US$ 285 Million in 2009.

*

The Chinese Insulin market is strongly oligopolistic with top three players (all of them being multinationals) accounting for 92% of the total sales in 2009. In fact, one player (Novo Nordisk) accounted 71% of the total sales.

Forecasts: The report provides forecasts on:

*

Number of diabetes patients

*

Diagnosis and treatment rates in China

*

Diabetes market

*

Non-Insulin Anti-diabetics market

*

Alpha-Glycosidase Inhibitors

*

Glinides

*

Glitazones

*

Sulphonylureas

*

DPP-IV Inhibhitors

*

Biguanides

*

GLP-1 Agonists

*

All other Non-Insulin Anti-diabetic classes

*

Insulin market

For more information please contact :

http://www.aarkstore.com/reports/China-Diabetes-Market-Report-Outlook-For-2010-2015-65420.html

http://blogs.aarkstore.com/

From:Aarkstore Enterprise

Contact: Neel

Email: press@aarkstore.com

URL: www.aarkstore.com

by: Aarkstore Enterprise

POST COMMENT

Career Advice For Graduates: How To Find A Job In Todays Market Aarkstore Enterprise---india Water Purifier Market Outlook 2014 Aarkstore Enterprise---india Power Market Outlook & Forecast 2014 Aarkstore Enterprise---poland Medical Tourism Market 2013 Aarkstore Enterprise---global Cloud Computing Services Market Outlook Social Media Marketing Company: Harnessing Social Media To Promote Your Brand Affiliate Marketing Is One Of The Best Ways To Make Money Online The Everlasting Thrills Of Bebo Kobo Market Aarkstore Enterprise---market Opportunity: Service Delivery Platforms (sdp) Tablet Pc Is Hard To Replace The Notebook Market Position Aarkstore Enterprise---service Delivery Platform (sdp) Solutions And Market Opportunities We Show The Market Your True Potential. Wondering If Fastin Is Just Another Scam